Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-145 + Plerixafor for Donor Stem Cell Mobilization in Hematologic Malignancies
NCT04762875Phase 2Terminated
- Sponsor
- Ensoma
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of MGTA-145 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by Ensoma. Started Jun 2021; status: terminated.
02
Drugs
MGTA-145
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04762875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762875.